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Vascular calcification is an undervalued risk factor for 
the appearance of cardiovascular disease (CVD). 
Regarded as a surrogate marker for atherosclerosis, a 
condition that frequently precedes coronary events [1], 
calcification is commonly seen in the vasculature of 
elderly subjects, and in middle-aged subjects with 
premature vascular disease associated to chronic kidney 
disease [2]. Hitherto, vascular calcification was thought 
to be a consequence of simple, physical mineral 
deposition in the vessel walls. New evidence, however, 
has revealed a highly regulated cellular response to be 
involved, and that calcification is the result of an 
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Vascular calcification is commonly seen in elderly people, though it can also appear in middle-aged subjects 
affected by premature vascular aging. The aim of this work is to test the involvement of microvesicles (MVs) 
produced by senescent endothelial cells (EC) and from plasma of elderly people in vascular calcification. The 
present work shows that MVs produced by senescent cultured ECs, plus those found in the plasma of elderly 
subjects, promote calcification in vascular smooth muscle cells. Only MVs from senescent ECs, and from elderly 
subjects' plasma, induced calcification. This ability correlated with these types of MVs' carriage of: a) increased 
quantities of annexins (which might act as nucleation sites for calcification), b) increased quantities of bone-
morphogenic protein, and c) larger Ca contents. The MVs of senescent, cultured ECs, and those present in the 
plasma of elderly subjects, promote vascular calcification. The present results provide mechanistic insights into 
the observed increase in vascular calcification-related diseases in the elderly, and in younger patients with 
premature vascular aging, paving the way towards novel therapeutic strategies. 
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imbalance between the inhibitors and inducers of Ca 
deposition [3]. The plasma calcium/phosphate (Ca/P) 
balance and the increase of proteins involved in bone 
formation (osteopontin, osteocalcin, certain proteogly-
cans, and bone morphogenetic protein 2 [BMP2]) [4], 
among other factors, have all been found involved [3]. 
 
Microvesicles (MVs) –also named microparticles- are a 
subset of extracellular vesicles [5]. Recent studies have 
shown that MVs produced by a smooth muscle cells, 
can carry Ca as well as molecules (P and proteins) that 
act as calcification nucleation sites. They may therefore 
also be involved in initiating vascular calcification [3, 
6]. Indeed, some MVs carry Ca-binding annexins, 
among them A2 and A6 [6, 7]. Endothelial senescence 
is known to be involved in the initiation of certain 
CVDs such as atherosclerosis and hypertension; the 
MVs produced by senescent ECs might therefore play 
an important role in their onset [8, 9]. Previous studies 
by our group have shown that microparticles produced 
by ECs in response to inflammatory stimuli, promote a 
calcifying response in vascular smooth muscle cells 
[10].  
 
The aim of the present study was to determine: 1) 
whether MVs produced by senescent, cultured ECs, 
plus those found in the plasma of elderly subjects, 
promote calcification in vascular smooth muscle cells, 





Quantification and characterization of plasma-
derived microvesicles  
 
Flow cytometric analysis of the plasma-derived MVs 
from both the young and elderly subjects localized the 
MVs population around the forward scatter signal 
corresponding to particles with a diameter of around 1 
 
 
Figure 1. Plasma MVs assessed by flow cytometry. (A) Representative dot plot showing log forward scatter (FSC) vs. log side 
scatter (SSC) localization of MVs in a young subject. The upper right gate shows the bead flow count, used as an index to count MVs 
in absolute terms. The lower left gate shows MVs smaller than 1 µm. (B) Representative dot plot showing localization of MVs in an 
elderly subject. 
 
Table 1: Demographic data and MVs (number /μL) from elderly and young subjects.  
Donors 
Age (years) 







Total MV Annexin A5+ 




















6959 ±1187*** 5254 ± 1051** 1850 ± 338*** 
*** p<0.001 vs Young, **p<0.01 vs Young 
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μm (Fig. 1). Figure 1B shows that the plasma of the 
elderly subjects contained a greater number of total 
MVs.  
 
As showed in Table 1, elderly subjects' MVs contained 
an increase total MVs (annexin A5+) compared with 
young subjects (6959±1187/µL vs 4868±547/µL; 
p<0.001). Additionally, significantly more of the elderly 
subjects' MVs carried annexin A5+/CD31+/CD42+ 
platelet-associated antigens (5254±1051/µL compared 
with 4176±661/µL of the young subjects' MVs; 
p=0.004). In addition, more carried endothelial-
associated annexin A5+/CD31+/CD42- antigens 
(1850±338/µL compared with 692±260/µL; p<0.001). 
 
Quantification and characterization of HUVEC-
derived microvesicles  
 
Cytometric characterization revealed most of these MVs 
showing a similar distribution from both young and 
senescent endothelial cells (representing a diameter of 1 
µm; Fig. 2A1 and 2B1). The number of total MVs in the 
culture medium of the senescent human umbilical vein 
endothelial cells (HUVEC) was greater than in that of 
the young cells (Fig. 2A2, 2B2 and 2C). These 
senescent HUVEC-derived MVs expressed more 
annexin A5+/CD31+ than those derived from young 
HUVEC (Fig. 2D). Based on the absence of fluorescent 
nuclear staining by acridine orange, only a small 
percentage of MVs (<10%) showed characteristics of 
apoptotic bodies. 
 
Microvesicles from senescent HUVEC and elderly 
subjects' plasma induce calcification in HASMC 
 
To determine the ability of MVs to promote 
calcification, human aortic smooth muscle cells 
(HASMC) were cultured in the presence of MVs 
(50,000 MVs/mL) from senescent or young endothelial 
HUVEC, (Fig. 3A). Only the MVs from the senescent 
HUVEC induced calcification in the HASMC. In fact, 
alizarin red deposits were observed after 6 days of 
treatment. These deposits were not observed in HASMC 
grown with MVs from the young HUVEC. HASMC 
were incubated with inorganic P (Pi), a pro-calcific 
condition,  as  positive  control;  in  the  negative control 
 
 
Figure 2. HUVEC-derived MVs assessed by flow cytometry.  Representative dot plots showing log forward scatter (FSC) vs. 
log side scatter (SSC) from young (A1) and senescent (B1) HUVEC. Representative dot plots showing annexin A5 and CD31 
phenotype from young (A2) and senescent (B2) HUVEC. (C) Absolute number of MVs per µL of sample from young and senescent 
HUVEC; *p<0.05. (D) Absolute number of CD31+/annexin A5+ MVs per µL of sample; *p<0.05. Results are presented as the mean ± 
SD of 6 independent experiments. 
 




Figure 3. MVs from senescent HUVEC cells induced calcification in HASMC. Cells were cultured with 50,000 MVs/mL from 
young (Y MV) or senescent (S MV) HUVEC for different times. (A) Qualitative calcification was stained with alizarin red. A 
representative experiment from six different experiments per duplicate is show. (B) Calcium content was determined by 
spectrophotometer by phenolsulphonephthalein dye at 6 and 9 days of treatment. The graphs present calcium content of the cells 
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HASMC were grown without MVs and Pi. This last 
control did not show red alizarin stain. A similar effect 
was observed using MVs (100,000 MVs/mL) from 
elderly and from young subjects.  
 
In order to quantify the process of calcification, calcium 
content was analysed using a colorimetric method 
containing phenolsulphonephthalein dye (Figure 3B). 
The calcium content was significantly increased in 
HASMC after 6 and 9 days of treatment with senescent 
HUVEC MVs. A similar effect was observed in pro-
calcific condition. 
 
Capture of HUVEC-derived microvesicles by 
HASMC 
 
HUVEC-derived MVs were labelled with CellTracker 
CM-Dil PI (red) and cultured for 48 h with HASMC to 
 
 
Figure 4. Capture of MVs by HASMC. Cells were incubated for 48 h with MVs from young (panels A1 and A2) or senescent 
HUVEC (panels B1 and B2) stained with CellTracker CM-Dil PI (red) and then were stained with phalloidin (PKH67, green). Nuclei 
were stained with DAPI (blue). Fluorescence was evaluated by confocal microscopy. (A) Scale bar 25µm, and (B) scale bar 10 µm. A 




Figure 5. Scanning electron microscopy. (A) Gold-palladium coated senescent MVs. Scale bar 1μm. Note the poly-L-lysine layer. 
(B and C) Young MVs prepared without metal coating. Note the heterogeneous size and brightness. Scale bar 5μm. The background 
noise of some pictures a consequence of the fast scanning speed. 
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determinate whether they promote calcification by 
adherence to the cell surface and/or by being 
endocytosed by the latter cells. After that HASMC were 
stained with PKH67 phalloidin (green). Confocal 
microscopy showed the majority of the MVs to locate 
inside the cytoplasmic compartment of the HASMC 
(Fig. 4). This was true for the MVs from both the young 
and senescent HUVEC.  
 
Senescent HUVEC-derived microvesicles carry Ca 
 
SEM analysis showed the HUVEC-derived MVs to be a 
heterogeneous population of spherical and elongated 
structures ranging from 0.2 to 1.8 μm along their 
longest axis (Fig. 5A). Large MVs were more 
commonly produced by senescent HUVEC than young 
HUVEC. Microanalysis revealed the MVs from all 
sources to have a heterogeneous atomic composition (as 
demonstrated by the heterogeneous brightness of the 
MVs; in EDS analysis, elements with a 
higher atomic number appear brighter because they emit 
more backscatter signal) (Fig. 5B and C). 
 
To determine the Ca content of the MVs, 60 young and 
senescent HUVEC-derived MVs were SEM-EDS-
analyzed in spot mode. This involves focusing a narrow 
electron beam at a specific point (spot) on the MV (Fig. 
6A). Some 67% of the senescent HUVEC-derived MVs 
had a high Ca content (i.e., >20% relative content). 
MVs with low Ca contents (3-10%) represented some 
25% of the total number; only 8% had no Ca. In 
contrast, 84% of the young HUVEC-derived MVs had 
no Ca; the remaining 16% contained a little Ca. These 
results agree with the Ca mapping results for both these 
types of MV (Fig. 6B1 and 2).  
 
Interestingly, TEM analysis revealed morphological 
differences between the MVs from the young and 
senescent HUVEC (Fig. 7). MVs from the former (Fig. 
7A) were generally spherical and showed a very simple 
internal structure. In contrast, few of the MVs from 
senescent HUVEC were spherical; indeed, a large 
number of irregular MVs were seen to contain even 
smaller vesicles of differing electron density (Fig. 7B). 
 
Senescent endothelial microvesicles contain pro-
calcification proteins 
 
Western blot assays showed the senescent HUVEC-
derived MVs to have more annexin A2 and annexin A6  
 
 
Figure 6. Spot mode microanalysis of an MV (A1) with its corresponding plot (A2); arrows indicate Ca spikes. Scale bar 5μm. Larger 
MVs are usually brighter and have a higher Ca content. Ca mapping of MVs from (B1) young and (B2) senescent HUVEC. Ca is seen 
as grey on the black background.  
 




Figure 8. (A) Western blot showing that BMP2, annexin A6 and annexin A2 carriage to be higher in MVs from senescent than from 
young HUVEC. Equal protein loading was confirmed using a HSP90 antibody. Total protein expression was obtained via 
densitometric analysis and expressed as the ratio protein/HSP90 in arbitrary units. n=3 pools; *p<0.05; **p<0.01. (B) Representative 
BMP2, annexin A6 and annexin A2 western blot of young and senescent HUVEC pools. Equal protein loading was confirmed probing 





Figure 7. TEM analysis of MVs from (A) young and (B) senescent HUVEC.  
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than those from the young cells. Similar results were 
seen for BMP2 (Fig. 8A). However, there was no 
change in protein expression of these proteins between 
young and senescent HUVEC (Fig. 8B). These findings 
suggest that MVs from senescent endothelial are 




It is thought that senescent ECs produce MVs 
containing compounds that may interfere with the 
function of vascular cells leading to CVDs [11-13]. In 
agreement, the present results suggest that the MVs 
circulating in the plasma of elderly subjects contribute 
towards the calcification of vascular smooth muscle 
cells. In addition, those obtained for the in vitro-
generated HUVEC MVs strongly support the idea that 
calcification associated with aging is triggered by the 
MVs produced by senescent ECs. Certainly, the 
senescent HUVEC MVs contained increased amounts 
of Ca and bone-associated proteins. They also carried 
increased amounts of phosphatidylserine (as shown by 
their marking with annexin A5), and were actively 
endocytosed by HASMC, which later showed signs of 
calcification. 
 
Compared to the younger subjects, the plasma of the 
elderly subjects contained a larger number of MVs in 
general, and of EC-produced MVs in particular, all 
cytometrically determined to be about 1 µm in diameter. 
Other authors have reported similar dimensions for a 
subset of MVs (microparticles) involved in CVD [11]. 
Increased numbers of MVs have also been reported in 
other patients with CVD, supporting the idea that they 
contribute to its appearance[14]. The present results 
contrast, however, with those of Forest et al.[15] The 
latter authors reported healthy elderly subjects to 
produce fewer endothelial MVs. It may be that minor, 
undetected illnesses, influence the production of MVs.  
 
Only the MVs from the plasma of elderly subjects, and 
from senescent HUVEC, promoted the calcification of 
HASMC. It was very difficult to isolate sufficient bona 
fide EC-derived MVs from the plasma in order to 
confirm their having a role in vascular calcification. 
However, more than sufficient such MVs were isolated 
from senescent HUVEC. 
 
Several studies have reported increased metabolic 
activity in senescent cells [16-18], which might explain 
why some of the MVs produced by them were slightly 
larger. Further, an increased amount of protein in MVs 
has been reported to be associated with a higher risk of 
future vascular events and mortality in patients with 
clinically manifested vascular disease [16-18]. Whether 
the amount of proteins in these MVs might help identify 
elderly subjects with increased risk of CVD needs to be 
evaluated. 
 
The Ca and BMP2 carried by the MVs of senescent 
HUVEC promote osteoblastic transformation of 
vascular smooth muscle cells [10, 19]. However, other 
calcification mechanisms may be involved. Some MVs 
might act as nodes within the extracellular matrix 
leading to its direct calcification, while others may enter 
the smooth muscle cells and then calcify their interior. 
Certainly, the first of these possible extra mechanisms is 
used by osteoblasts and chondrocytes to mineralize the 
extracellular matrix [20]. Intracellular calcification has 
been documented long time ago [21] and also occurs 
under physiological conditions in different species [22]. 
Further, a predominantly intracellular form of 
calcification has been described to occur in the early 
stages of calcification in cell cultures [23]. It may 
therefore be that different MVs use these different 
mechanisms; the enormous heterogeneity of MVs 
would appear to support this hypothesis. 
 
It has been reported that calcification-mediating MVs 
carry extra Ca-binding proteins such as annexin A2 and 
A6 [6, 7]; this was confirmed in the present work. 
Annexin A6 is abundant at sites of vascular 
calcification, a process that is decelerated by siRNA 
depletion of this protein [7]. Ca-containing MVs have 
been identified in a range of cells [7, 24, 25], and to be 
induced by pathological or apoptotic signals. However, 
the production of Ca-containing MVs by senescent ECs 
is spontaneous and associated with cell aging. 
 
The present results suggest that, with age, the number of 
MVs in the plasma increases, promoting vascular 
calcification. These MVs are likely produced by 
senescent ECs. Clinical studies are required to 
determine whether the number of calcifying MVs 
correlates with vascular calcification in elderly patients, 
and in those with premature vascular disease. The 
results also suggest that MVs could be used as markers 
of vascular calcification; their detection might be used 
to identify patients at risk of CVD and/or follow the 
clinical course of their disease. They also suggest that 
MVs might offer a therapeutic target for the control of 






The study subjects were 26 non-smoking volunteers 
with normal body mass indices. Fifteen were aged 20–
28 years, and 11 were aged 75–83 years (Table 1). All 
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were healthy according to analytical criteria and their 
responses to a medical questionnaire; certainly none had 
any cardiovascular, autoimmune, metabolic, inflamma-
tory or kidney disease. None took any medication (not 
even the elderly subjects). The local Scientific Ethics 
Committee approved the present research protocol. All 
subjects provided written, informed consent to be 
included. 
 
Blood samples  
 
Venous blood samples were drawn from both elderly 
and younger subjects into EDTA-coated tubes. Platelet-
free plasma (PFP) was prepared at room temperature by 
serial centrifugation (15 min at 1500 x g, followed by 2 
min at 13,000 x g). The supernatant was stored in 1.5 






HUVEC (ATCC Cat No.PCS-100-010) were cultured in 
endothelial growth medium (EGM) (Lonza) 
supplemented with 10% heat-inactivated foetal bovine 
serum (FBS) (Sigma). Cultures were maintained at 
37°C in a 5% CO2 atmosphere at 95% humidity.  
 
First-passage cryopreserved HUVEC were grown and 
serially passaged until they reached senescence (the 
replicative senescence model). Cells passaged <8 times 
(population doubling [PD]<20.48; with PD calculated 
as [ln{number of cells harvested} − ln{number of cells 
seeded})/ln2]) were regarded as young ECs, and those 
passaged 26-38 times (PD>96.80) were regarded as 
senescent ECs [26, 27]. In these cells, the proliferation 
rate is remarkably reduced, and more than 75% are 
positive for senescence-associated β-galactosidase. 
 
Smooth muscle cells 
 
HASMC were obtained from Lonza (cc-2571). Cells 
were maintained in SmGM-2 medium (Lonza; cc-3181) 
supplemented with 20% FBS (Sigma) at 37°C in a 
humidified atmosphere with 5% CO2. HASMC of 
passage 5– 8 were used in the experiments. 
 
Isolation, quantification and characterization of 
microvesicles  
 
Plasma-derived and HUVEC-derived (isolated from the 
culture medium) MVs were isolated and counted using 
the quantification method based in the previously 
published for of the International Society on 
Thrombosis and Haemostasis [28], with minor 
modifications. Platelet-free plasma (PFP) was obtained 
as previous described ("Blood samples" in Methods 
section). Next, MVs from PFP was isolated by 
centrifugation (13,000 g for 30 min). Furthermore, MVs 
from HUVEC were obtained from supernatants were 
centrifuged at 13,000 g for 30 min as described 
previously. 
 
Pooled MVs (i.e., from elderly subjects' plasma, from 
young subjects' plasma, from the medium of young 
HUVEC cultures, and from that of senescent HUVEC 
cultures) were characterized in terms of size using a 
Beckman Coulter Cytomic FC 500 flow cytometer 
running CXP software. MVs were understood to be 
those events gated with a size between 0.5-1.5 µm; this 
gate was established from the side scatter (SSC) vs. 
forward scatter (FSC) dot-plot produced in a 
standardization experiment using the SPHERO™ Flow 
Cytometry Nano Fluorescent Size Standard Kit 
(Spherotech). The latter has size-calibrated fluorescent 
beads ranging from 0.1-1.9 µm in diameter. Events 
below 0.2 µm were excluded in order to adequately 
distinguish true events from the background; events 
>1.9 µm were excluded to prevent possible confusions 
with apoptotic bodies. The absolute number of MVs 
(events) per microliter was determined using Flow 
Count Calibrator beads (10 µm; Beckman Coulter Inc.) 
according to the manufacturer's recommendations using 
CXP software: (MVs counted x standard 
beads/L)/(standard beads counted). Data were recorded 
as the mean of three independent measurements of the 
same sample. 
 
Triple-fluorescent labelling was performed to 
characterise the protein profile of the plasma MVs and 
thus determine their cellular origin. This was done by 
incubating platelet-free plasma (100 µL) with 
fluorescein isothiocyanate-conjugated (FITC) labelled 
monoclonal anti-CD31 (BD Pharmingen), peridinin 
chlorophyll protein complex (PerCP) monoclonal anti-
CD42b (Abcam), and phycoerythrin-annexin A5 (BD 
Pharmingen), together in annexin A5-binding buffer (10 
mM HEPES, 7.4 pH, 140 mM NaCl, 2.5 mM CaCl2). 
Isotype negative controls were also prepared. Since 
CD31 is expressed by both platelets and ECs, but CD42 
occurs only in platelets, platelet MVs were defined by 
events CD31+/CD42+ and endothelial MVs by events 
CD31+/CD42-. As a control for the annexin A5 
labeling, a sample with fluorescein-conjugated annexin 
A5 using a CaCl2-free solution was established. 
 
MVs from HUVEC culture medium were isolated and 
characterized with respect to size and in terms of their 
protein profile using FITC-anti-CD31 and 
phycoerythrin-annexin A5, as above.  
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To confirm the exclusion of apoptotic bodies in MVs 
isolations, the DNA content of the HUVEC-derived 
MVs was determined by incubating them with acridine 
orange (Invitrogen) to a final concentration of 20 mM. 
 
Western blot analyses  
 
Extracts from young and from senescent endothelial 
cells, and MVs from young and from senescent 
HUVEC were lysed in CytoBuster Protein Extraction 
Reagent lysis buffer (Millipore) containing protease and 
phosphatase inhibitor cocktail (Roche). The total 
protein content of lysates was quantified using a BCA 
Protein Assay Kit (Pierce), with BSA as the standard. 
Briefly, equal amounts of protein (10-50 μg 
protein/lane) were diluted with reducing sample buffer 
and separated by SDS/PAGE (10% gel) under reducing 
conditions. Samples were then transferred onto 
nitrocellulose membranes (BioRad), blocked in TBS 
containing 0.1% Tween 20 and 5% dry non-fat milk for 
1 h at room temperature, and incubated in the same 
buffer with different primary antibodies (BMP2, Abcam 
ab82511, dilution 1:1000, 46 kDa; annexin A6, Abcam 
ab31026, dilution 1:1,000, 76kDa; annexin A2, Abcam 
ab41803, dilution 1:1000, 38 kDa). Anti-β-actin (Santa 
Cruz) (sc-47778, dilution 1:2000, 43 kDa) or GAPDH 
(Millipore) MAB374, dilution 1:2000, 38 kDa) was 
used as a loading control for endothelial cells, and anti-
HSP90 (Cell Signaling) (CST#4874, dilution 1:1000, 90 
kDa) was used as a loading control for MVs. After 
washing, the membranes were incubated with Novex 
horseradish peroxidase-conjugated secondary antibodies 
(1:5000). Bands were visualized with Luminata 
Crescendo Western HRP substrate (Millipore). The 
quality of proteins and efficacy of protein transfer was 
evaluated by Red Ponceau staining. Bands were 
quantified using Image J software (NIH) and 
normalized to anti-HSP90 in MVs and anti-GAPDH or 




The qualitative staining of HASMC calcification was 
identified by alizarin red. HASMC (10000 cells/well, 
24-well plates) were cultured with 100,000 MVs/mL 
from the plasma of young or elderly subjects, or with 
50,000 MVs/mL from young or senescent HUVEC for 
1, 3, 6 and 9 day in 2% FBS-supplemented DMEM. As 
a positive control, cells were exposure with 2% FBS-
supplemented DMEM containing 2.0mM Pi (pro-
calcific condition). Culture medium was renewed every 
2 days. Detection and quantification of mineral 
deposition were performed using alizarin red staining. 
Briefly, samples were fixed (50% ethanol 5 min, 95% 
ethanol 5 min), stained for 5 min with alizarin red S 
(40 mM, pH 4.2), rinsed with 50% ethanol, and 
subsequently scanned.  
 
Assessment of calcium deposition  
 
After 6 and 9 days of incubation, calcification was 
quantified. Cells were decalcified with 0.6 N HCl 
overnight at 4°C. The Ca content of the supernatants 
was determined by spectrophotometer by a kit 
containing phenolsulphonephthalein dye (no. DICA-
500, QuantiChrom calcium assay kit; BioAssay 
Systems). Then, the cells were washed three times with 
PBS (Sigma) and solubilized in 0.1 M NaOH/1% SDS. 
The protein content was measured using the BCA 
protein assay kit (Pierce), and the Ca content was 
normalized for total protein. Ca content of the cells was 




MVs from young and from senescent HUVEC were 
stained with CellTracker CM-Dil (LifeTechnologies) to 
visualize interactions between the MVs and HASMC. 
The latter cells were cultured with the stained MVs for 
48 h, washed with PBS, and then stained with 
phalloidin-FITC (PKH67). They were then fixed with 
4% paraformaldehyde solution in PBS, and mounted in 
gold antifade reagent plus DAPI. Fluorescence was 
detected using a confocal microscope (Leica 
Microsystems GmbH). 
 
Electron microscopy  
 
Clean, dry coverslips (12 mm diameter) were coated 
with poly-L-lysine (70,000-150,000 Da) using a 0.1% 
solution of the same (Sigma). A water-repellent circle 
of approximately 6 mm diameter was then drawn on the 
coated coverslip using a pap pen. One drop of 
suspension of MVs from young or senescent HUVEC 
(6000 MVs/mL) was then placed within this circle and 
incubated for 1 h in a humidified chamber at room 
temperature. After a brief wash in PBS, the MVs were 
fixed in 3% glutaraldehyde for 10 min, rinsed in buffer, 
dehydrated in an ethanol series and dried following the 
routine critical point drying procedure for scanning 
electron microscopy (SEM). For morphological 
analysis, the prepared MVs were gold-palladium coated 
(theoretical thickness 5 nm) in a Polaron E5400 metal 
evaporator (BioRad), and examined using a Zeiss DSM 
950 SEM.  
 
For Ca microanalysis, non-metal-coated MVs were 
prepared using a Hitachi TM-1000 SEM with an EDS 
system. For Ca mapping, MVs samples were fixed in 
70% ethanol and deposited on a formvar-coated copper 
grid and analysed using a Zeiss LEO 906E transmission 
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electron microscope (TEM) equipped with an elemental 
analysis environmental module.  
 
For ultrastructual analysis, samples were fixed in 2.5% 
(v/v) glutaraldehyde and 0.05% (w/v) ruthenium red in 
0.05 M sodium cacodylate buffer for 4 h at 4°C. They 
were then post-fixed with 1% (w/v) OsO4 in 0.1 M 
sodium cacodylate buffer for 1 h at room temperature, 
dehydrated in ethanol, and infiltrated with resin. 
Ultrathin sections were cut using a Reichert Jung E 
ultramicrotome. Finally, the sections were stained for 
10 min with 1% (w/v) aqueous uranyl acetate solution 





Data are expressed as means±SEM and analysed by 
ANOVA followed by the Duncan test. Comparisons 
between pairs of means were performed using the 
Student t test or Mann–Whitney U test as required. 
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